ARK Invest reduces its stake in Strata Critical Medical as analysts predict 120% upside
RV
Remy Villiers
Cathie Wood · Apr 14, 2026
Source: DojiDoji Data Terminal
ARK Invest ETFs sold 182,767 shares of Strata Critical Medical (SRTA) on April 13, totaling a combined value of $738,378. This sale follows a sale of more than 75,000 shares on April 10. The shares were sold through the ARK Autonomous Technology & Robotics ETF (ARKQ) and the ARK Space Exploration & Innovation ETF (ARKX).
B. Riley analyst Yuan Zhi initiated coverage of the company with a Buy rating and an $8 price target, citing the company's position as the only end-to-end platform in organ transplant logistics. Craig-Hallum analyst Bill Bonello also initiated coverage with a Buy rating and an $8 price target.
Wall Street has a Strong Buy consensus rating on the stock based on three unanimous Buy recommendations. Based on an average price target of $9.08, analysts see over 120% upside from the current share price of $4.12.
Cathie Wood
The Ledger Morning
The essential intelligence to start your trading day. Delivered 6:00 AM EST.
Join 50,000+ professionals who start their day with The Digital Ledger.